Balp.Ns

BALP.NS has a debt-to-equity ratio of 1.94, indicating a capital structure that is significantly leveraged, with liabilities exceeding equity by a wide margin. The company's liquidity position is assessed as medium, with a current ratio of 1.07, suggesting it has just enough current assets to cover its current liabilities. However, the company's free cash flow is negative at -36.9 million INR, and its operating cash flow is only 203.15 million INR, which may limit its ability to fund operations without external financing.

In terms of profitability, BALP.NS has a return on equity (ROE) of 9.32%, which is relatively strong, but its return on assets (ROA) is only 2.15%, indicating that the company is not efficiently using its assets to generate profits. These metrics are compared against the industry's preferred metrics, which typically emphasize ROE and ROA as key indicators of financial performance. The company's ROE is above the median for the pharmaceutical industry, but its ROA is below the median, suggesting that asset utilization is a key area for improvement.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic breakdown provided in the available data. This lack of diversification may expose the company to higher risk if demand in its primary market fluctuates. There is no information available on geographic revenue distribution, which is a common disclosure in the pharmaceutical industry.

BALP.NS has shown a growth trajectory in recent periods, with a revenue of 3.03 billion INR. However, the outlook for the next fiscal year is not explicitly provided in the available data. The company's capital expenditure of -187.87 million INR indicates a reduction in investment in physical assets, which may signal a strategic shift or financial constraint. The company's operating income of 197.89 million INR and net income of 72.15 million INR suggest that it is profitable, but the margins are relatively thin compared to industry benchmarks.

The risk assessment for BALP.NS highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could impact its ability to meet short-term obligations without additional financing. The dilution risk is low, as the number of shares outstanding has not changed between basic and diluted shares, indicating no imminent threat of share dilution. The company's financial structure and cash flow position suggest that it may need to manage its debt levels carefully to maintain financial stability.

Recent events and filings for BALP.NS are not detailed in the available data, but the company's financial statements and risk assessment suggest that it is navigating a period of financial constraint and strategic adjustment. The company's free cash flow is negative, and its capital expenditures have decreased, which may indicate a focus on cost control and asset optimization. The company's liquidity position is a key area of concern, and it may need to secure additional financing or improve its cash flow to maintain operations.